Physician profile
John M Willis
NPI 1205891207
$2,312.53
in general payments reported to CMS, 2019-2025
30 companies · $544 in 2025
The $544 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $225 · 2021: $50.33 · 2022: $156 · 2023: $34.96 · 2024: $386 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $425.06 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $311.71 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $285.27 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $200.67 | 2019-2025 | |
| Abbott Laboratories | $146.80 | 2019-2025 | Freestyle Libre, Proclaim |
| Amgen INC. | $101.03 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $88.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $72.23 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $63.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.07 | 2019-2020 | |
| Alkermes, INC. | $45.51 | 2020-2025 | Vivitrol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.80 | 2025 | Jardiance |
| Allergan, INC. | $41.58 | 2020 | |
| Sanofi Pasteur INC. | $41.39 | 2019 | |
| Indivior INC. | $41.31 | 2025 | Sublocade |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $41.03 | 2019-2020 | |
| Amarin Pharma, INC. | $40.03 | 2019 | |
| Antares Pharma, INC. | $35.30 | 2019 | |
| Inspire Medical Systems, INC. | $34.96 | 2023 | Inspire |
| Nalpropion Pharmaceuticals LLC | $26.41 | 2019 | |
| Verity Pharmaceuticals INC. | $26.00 | 2024 | Tlando |
| Titan Pharmaceuticals, INC. | $24.55 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.32 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $17.19 | 2025 | Gardasil 9, M-M-R II, Capvaxive |
| Teva Pharmaceuticals USA, INC. | $14.94 | 2019 | |
| Mdd US Operations, LLC | $13.94 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.90 | 2020 | |
| Exact Sciences Corporation | $13.70 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.24 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.